Preventing stalling to improve CAR-T cells’ efficacy against tumors

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient’s own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup